reports that patients with lower expression of CD8+PD-1+ T-cells had a better response to CAR-T, suggesting that the inhibitory effect of PD-1 signaling plays a role in controlling the anti-tumor effect of CAR-T therapy (81). The gene discussed is CD8A; the disease is neoplasm.